David Johnson, MD
Internal Medicine · Owensboro, KYNPI 1215933247
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $924 of the $1,036 with a category attached, or 89.2%. It is spread thinly across 22 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $363 and has fallen 76.8% since, to $84 in 2025.
Across 73 payments — averaging $14.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$152
- Amarin Pharma, Inc.$119
- Medtronic$112
- Amgen$111
- GSK$76
- Takeda Pharmaceuticals U.S.A., Inc.$61
- plus $406 from 16 others
Across 39 payments — averaging $20,160 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$343K
- AstraZeneca$276K
- Sage Therapeutics, LLC$77K
- Lexicon Pharmaceuticals, Inc.$51K
- Novartis$27K
- Swedish Orphan Biovitrum AB$10K
- plus $2K from 1 others
What the payments were for
- Food & beverage$92489%
- Education$11211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 9 | $152 |
| Amarin Pharma, Inc. | 20 | $119 |
| Medtronic | 1 | $112 |
| Amgen | 8 | $111 |
| GSK | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $61 |
| Novartis | 3 | $48 |
| Inspire Medical Systems, Inc. | 2 | $48 |
| Abbott | 2 | $43 |
| Ironshore Pharmaceuticals Inc. | 1 | $39 |
| Lilly USA, LLC | 2 | $31 |
| Exact Sciences | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Nevro Corp. | 1 | $25 |
| AbbVie | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Novo Nordisk | 1 | $12 |
| Endogastric Solutions, Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,036 in reported general payments places this provider in the 65th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 174 | $226,200 |
| EliquisApixaban | 209 | $191,742 |
| JanuviaSitagliptin Phosphate | 133 | $116,862 |
| JardianceEmpagliflozin | 137 | $113,998 |
| TrulicityDulaglutide | 50 | $76,677 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $62,023 |
| FarxigaDapagliflozin Propanediol | 47 | $55,846 |
| MounjaroTirzepatide | 43 | $52,903 |
| XareltoRivaroxaban | 67 | $51,963 |
| MyrbetriqMirabegron | 62 | $36,077 |
| LinzessLinaclotide | 42 | $32,334 |
| Repatha SureclickEvolocumab | 42 | $32,294 |
| Xtampza ErOxycodone Myristate | 12 | $24,741 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $24,254 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 98 | $18,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $12 | $226,200174 claims |
| PfizerEliquis, Premarin | $152 | $196,505220 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $31 | $129,58093 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $76 | $86,277126 claims |
| Johnson & JohnsonXarelto, Invokana | $13 | $59,02979 claims |
| AbbVieLinzess, Synthroid, Savella | $15 | $47,043222 claims |
| NovartisEntresto | $48 | $9,46214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Owensboro
- Bernard BuchananOwensboro$185K
- Jeremy LuckettOwensboro$12K
- Fares KhaterWhitesburg$412K
- David ManninoLexington$168K
- John PeppinCynthiana$108K
- Sanjay KaulBrownsville$69K
- John JonesHazard$63K
- Robert SasserLouisville$62K
- Justin LandeDanville$60K
- Sanjiv GuptaGrayson$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.